^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    A-319

    i
    Other names: A-319, A319, A 319
    Company:
    ITabMed
    Drug class:
    CD3 agonist, CD19 inhibitor
    Related drugs:
    3ms
    Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=25, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    A-319
    5ms
    Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=25, Recruiting, Wuhan Union Hospital, China | Trial primary completion date: May 2025 --> May 2026
    Trial primary completion date
    |
    A-319
    8ms
    Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=25, Recruiting, Wuhan Union Hospital, China | N=18 --> 25
    Enrollment change
    |
    A-319
    over1year
    Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=9, Recruiting, Wuhan Union Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    A-319
    over1year
    Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Wuhan Union Hospital, China
    New P1 trial
    |
    A-319
    2years
    Safety and Efficacy of a-319 (a CD3xCD19 T cell engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (ASH 2023)
    A-319 has the same mechanism of action as that of blinatumomab, and may benefit B-NHL patients. A-319 was well tolerated in relapsed/refractory B-NHL. A-319 at the dose level of 1. 2 ug/kg/day showed encouraging disease control and warranted further clinical investigation.
    Clinical
    |
    Blincyto (blinatumomab) • A-319